CC BY 4.0 · Rev Bras Ginecol Obstet 2022; 44(12): 1102-1109
DOI: 10.1055/s-0042-1755462
Original Article
Endoscopy

Misoprostol Administration Before Hysteroscopy Procedures – A Retrospective Analysis

O uso do misoprostol prévio aos procedimentos histeroscópicos – Um estudo retrospectivo
1   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
,
1   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
,
1   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
,
1   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
,
1   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
,
1   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
,
1   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
› Author Affiliations

Abstract

Objective To evaluate the use of misoprostol prior to hysteroscopy procedures regarding technical ease, the presence of side effects, and the occurrence of complications.

Methods This is a retrospective, observational, analytical, case-control study, with the review of medical records of 266 patients followed-up at the Gynecological Videoendoscopy Sector of the Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto of the Universidade de São Paulo (HCFMRP – USP, in the Portuguese acronym) from 2014 to 2019, comparing 133 patients who used the drug before the procedure with 133 patients who did not.

Results The occurrence of postmenopausal uterine bleeding was the main indication for hysteroscopy and revealed a statistical difference between groups (p < 0.001), being present in 93.23% of the patients in the study group and in 69.7% of the patients in the control group. Only 2 patients (1.5%) in the study group reported adverse effects. Although no statistical differences were observed regarding the occurrence of complications during the procedure (p = 0.0662), a higher total number of complications was noted in the group that used misoprostol (n = 7; 5.26%) compared with the group that did not use the drug (n = 1; 0.75%), a fact that is clinically relevant. When evaluating the ease of the technique (measured by the complete performance of all steps of the hysteroscopy procedure), it was verified that although there was no difference between groups (p = 0.0586), the control group had more than twice as many incompletely performed procedures (n = 17) when compared with the group that used misoprostol previously (n = 8), which is also clinically relevant.

Conclusion The use of misoprostol prior to hysteroscopy in our service indicated that the drug can facilitate the performance of the procedure, but not without side effects and presenting higher complication rates.

Resumo

Objetivo Avaliação do misoprostol prévio à histeroscopia quanto à facilidade técnica, efeitos colaterais e a ocorrência de complicações durante o procedimento.

Métodos Estudo analítico observacional retrospectivo tipo caso controle com revisão de prontuários de 266 pacientes do Setor de Videoendoscopia Ginecológica do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo (HCFMRP – USP), de 2014 a 2019, sendo comparadas 133 pacientes que utilizaram o medicamento prévio ao procedimento com 133 pacientes que não o utilizaram.

Resultados Sangramento uterino após a menopausa foi a principal indicação de histeroscopia, apresentando diferença estatística (p < 0,001), estando presente em 93,23% das pacientes do grupo de estudo e em 69,17% das pacientes do grupo controle. Apenas 2 pacientes (1,5%) do grupo de estudo relataram efeitos adversos. Não foram observadas diferenças quanto à presença de complicações durante o procedimento (p =  0,0662), mas observamos um número total de complicações maior no grupo de estudo (n = 7; 5,26%) do que no grupo controle (n = 1; 0,75%), o que é clinicamente relevante. Não houve diferença entre os grupos quanto à facilidade técnica (p = 0,0586), mas o grupo controle apresentou mais do que o dobro de procedimentos não completamente realizados (n = 17) quando comparado com o grupo de estudo (n = 8), o que é clinicamente relevante.

Conclusão O uso de misoprostol prévio à histeroscopia no nosso serviço demonstrou que ele pode facilitar a realização do procedimento, mas não é isento de efeitos colaterais e apresenta maiores taxas de complicações.

Contributions

All authors contributed to the design of the study, were involved in the data collection, data analysis and/or interpretation. Also, all authors contributed to the writing/substantive editing and review of the manuscript and approved the final draft of the manuscript.




Publication History

Received: 19 March 2022

Accepted: 26 March 2022

Article published online:
29 August 2022

© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 
  • References

  • 1 Martins FN, Martins NN. Histeroscopia diagnóstica [Internet]. Coimbra: Federação das Sociedades Portuguesas de Obstetrícia e Ginecologia; 2010 [cited 2021 Dec 12]. p. 359-71. Available from: http://www.fspog.com/fotos/editor2/cap_42.pdf
  • 2 Ganer Herman H, Kerner R, Gluck O, Feit H, Keidar R, Bar J. et al. Different routes of misoprostol for same-day cervical priming prior to operative hysteroscopy: a randomized blind trial. J Minim Invasive Gynecol 2017; 24 (03) 455-460 DOI: 10.1016/j.jmig.2016.12.024.
  • 3 Valente EP. Uso de misoprostol vaginal para redução da dor em histeroscopia diagnóstica na menacme: ensaio clínico randomizado, triplamente mascarado, controlado com placebo [dissertação]. Recife: Instituto Materno Infantil Professor Fernando Figueira; 2017
  • 4 Bastu E, Celik C, Nehir A, Dogan M, Yuksel B, Ergun B. Cervical priming before diagnostic operative hysteroscopy in infertile women: a randomized, double-blind, controlled comparison of 2 vaginal misoprostol doses. Int Surg 2013; 98 (02) 140-144 DOI: 10.9738/INTSURG-D-12-00024.1.
  • 5 Zhuo Z, Yu H, Jiang X. A systematic review and meta-analysis of randomized controlled trials on the effectiveness of cervical ripening with misoprostol administration before hysteroscopy. Int J Gynaecol Obstet 2016; 132 (03) 272-277 DOI: 10.1016/j.ijgo.2015.07.039.
  • 6 Fradique A. Histeroscopia cirúrgica [Internet]. Coimbra: Federação das Sociedades Portuguesas de Obstetrícia e Ginecologia; 2010 [cited 2021 Dec 12]. p. 511-33. Available from: http://www.fspog.com/fotos/editor2/cap_49.pdf
  • 7 Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA 2002; 288 (13) 1610-1621 DOI: 10.1001/jama.288.13.1610.
  • 8 Allen R, O'Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol 2009; 2 (03) 159-168
  • 9 Costa AA. Estudo randomizado, duplamente mascarado, placebo controlado do uso do misoprostol versus placebo para histeroscopia diagnóstica em mulheres na pós-menopausa [tese]. Campinas: Universidade Estadual de Campinas; 2006
  • 10 Moreira AR. O uso de misoprostol em histeroscopia: revisão do seu papel em contexto diagnóstico e cirúrgico [monografia]. Porto: Universidade do Porto; 2018
  • 11 de Albuquerque LG, Hardy E, Bahamondes L. Histerossonografia: avaliação da cavidade uterina com sangramento anormal. Rev Assoc Med Bras (1992) 2006; 52 (04) 247-250 DOI: 10.1590/S0104-42302006000400025.
  • 12 Angioni S, Loddo A, Milano F, Piras B, Minerba L, Melis GB. Detection of benign intracavitary lesions in postmenopausal women with abnormal uterine bleeding: a prospective comparative study on outpatient hysteroscopy and blind biopsy. J Minim Invasive Gynecol 2008; 15 (01) 87-91 DOI: 10.1016/j.jmig.2007.10.014.
  • 13 Koch DM, Rattmann YD. Uso do misoprostol no tratamento da hemorragia pós-parto: uma abordagem farmacoepidemiológica. Einstein (Sao Paulo) 2020; 18: eAO5029 DOI: 10.31744/einstein_journal/2020AO5029.
  • 14 Souza AS, Amorim MM, Costa AA, Noronha Neto C. Farmacocinética e farmacodinâmica do misoprostol em obstetrícia. Femina 2019; 37 (12) 679-684
  • 15 Batukan C, Ozgun MT, Ozcelik B, Aygen E, Sahin Y, Turkyilmaz C. Cervical ripening before operative hysteroscopy in premenopausal women: a randomized, double-blind, placebo-controlled comparison of vaginal and oral misoprostol. Fertil Steril 2008; 89 (04) 966-973 DOI: 10.1016/j.fertnstert.2007.03.099.
  • 16 Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. Am J Obstet Gynecol 1988; 158 (3 Pt 1): 489-492 DOI: 10.1016/0002-9378(88)90011-7.
  • 17 Bezerra Júnior AL, Costa AA, Fernandes GC, Santos JV, Pereira TM. Resultados intra e pós-operatórios e a frequência de complicações em pacientes pré e pós-menopausadas submetidas à histeroscopia cirúrgica no IMIP [tcc]. Recife: Instituto Materno Infantil de Pernambuco; 2019
  • 18 De Silva PM, Wilson L, Carnegy A, Smith PP, Clark TJ. Cervical dilatation and preparation prior to outpatient hysteroscopy: a systematic review and meta-analysis. BJOG 2021; 128 (07) 1112-1123 DOI: 10.1111/1471-0528.16604.
  • 19 Selk A, Kroft J. Misoprostol in operative hysteroscopy: a systematic review and meta-analysis. Obstet Gynecol 2011; 118 (04) 941-949 DOI: 10.1097/AOG.0b013e31822f3c7b.
  • 20 Song T, Kim MK, Kim ML, Jung YW, Yoon BS, Seong SJ. Effectiveness of different routes of misoprostol administration before operative hysteroscopy: a randomized, controlled trial. Fertil Steril 2014; 102 (02) 519-524 DOI: 10.1016/j.fertnstert.2014.04.040.
  • 21 Propst AM, Liberman RF, Harlow BL, Ginsburg ES. Complications of hysteroscopic surgery: predicting patients at risk. Obstet Gynecol 2000; 96 (04) 517-520 DOI: 10.1016/s0029-7844(00)00958-3.
  • 22 Jansen FW, Vredevoogd CB, van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 2000; 96 (02) 266-270 DOI: 10.1016/s0029-7844(00)00865-6.
  • 23 Agostini A, Bretelle F, Cravello L, Ronda I, Roger V, Blanc B. [Complications of operative hysteroscopy]. Presse Med 2003; 32 (18) 826-829
  • 24 Oppengard KS, Nesheim BI, Istre O, Qvigstad E. Comparison of self-administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design. BJOG 2008; 115 (05) 663 ,e 1–9 DOI: 10.1111/j.1471-0528.2007.01628.x.
  • 25 Fernandez H, Alby JD, Tournoux C, Chauveaud-Lambling A, DeTayrac R, Frydman R. et al. Vaginal misoprostol for cervical ripening before operative hysteroscopy in pre-menopausal women: a double-blind, placebo-controlled trial with three dose regimens. Hum Reprod 2004; 19 (07) 1618-1621 DOI: 10.1093/humrep/deh302.
  • 26 Uckuyu A, Ozcimen EE, Sevinc FC, Zeyneloglu HB. Efficacy of vaginal misoprostol before hysteroscopy for cervical priming in patients who have undergone cesarean section and no vaginal deliveries. J Minim Invasive Gynecol 2008; 15 (04) 472-475 DOI: 10.1016/j.jmig.2008.03.001.
  • 27 Costa HdeL, Costa LO. [Hysteroscopy in menopause: analysis of the techniques and accuracy of the method]. Rev Bras Ginecol Obstet 2008; 30 (10) 524-530 DOI: 10.1590/s0100-72032008001000008.
  • 28 Fouda UM, Elsetohy KA, Elshaer HS, Hammad BEM, Shaban M, Youssef MA. et al. Misoprostol prior to diagnostic office hysteroscopy in the subgroup of patients with no risk factors for cervical stenosis: a randomized double-blind placebo-controlled trial. Gynecol Obstet Invest 2018; 83 (05) 455-460 DOI: 10.1159/000480234.